@article{TAU6784,
author = {Isuru S. Jayaratna and Neema Navai and Colin P. N. Dinney},
title = {Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer},
journal = {Translational Andrology and Urology},
volume = {4},
number = {3},
year = {2015},
keywords = {},
abstract = {Muscle invasive bladder cancer (MIBC) is an aggressive disease that frequently requires radical cystectomy (RC) to achieve durable cure rates. Surgery is most effective when performed in organ-confined disease, with the best outcomes for those patients with a pT0 result. The goals of neoadjuvant chemotherapy (NC) are to optimize surgical outcomes for a malignancy with limited adjuvant therapies and a lack of effective salvage treatments. Despite level 1 evidence demonstrating a survival benefit, the utilization of NC has been hampered by several issues, including, the inability to predict responders and the perception that NC may delay curative surgery. In this article, we review the current efforts to identify patients that are most likely to derive a benefit from NC, in order to create a risk-adapted paradigm that reserves NC for those who need it.},
issn = {2223-4691}, url = {https://tau.amegroups.org/article/view/6784}
}